Porcine hemagglutinating encephalomyelitis coronavirus (PHEV) is a member of the *Coronaviridae* family; it is an enveloped virus containing a non-segmented, single-stranded, positive-sense RNA genome of approximately 30 kb that codes for 5 major proteins: Hemagglutinin-esterase protein (HE), Spike glycoprotein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N). NS4.9 and NS12.7, however, are non-structural proteins. The genes that encode these proteins occur in the order 5′-HE-S-NS4.9-NS12.7-E-M-N-3′ (GenBank accession no.: [NC_007732](ncbi-n:NC_007732)). PHEV was first isolated in 1962 in Canada from suckling piglets with encephalomyelitis and has since been isolated from swine worldwide. It was first isolated in primary cultures of pig kidney (PK-15) cells through visible cytopathic effects (CPE) and infectivity assays ([@bib0035], [@bib0065]). When piglets younger than 3 weeks are infected with PHEV, their mortality rates range from 20 to 100% ([@bib0070]).

RNA interference (RNAi) is an accurate and potent gene silencing method that uses double-stranded RNA (dsRNAs) molecules consisting of 19--27 nucleotides (nt) ([@bib0045]). Subsequent RNAi studies have used synthetic small interfering RNAs (siRNAs) or short hairpin RNAs (shRNAs) extensively to study the interference of viral replication. Thus far, the replication of various viruses, including many coronaviruses, has been effectively inhibited in vitro and *in vivo* ([@bib0025], [@bib0135], [@bib0050], [@bib0100], [@bib0115], [@bib0125], [@bib0120], [@bib0130]); however, no reports have shown that the replication of PHEV in cell culture could be disrupted by shRNAs targeting the N gene of PHEV.

N is an extensively phosphorylated, highly basic, vital structural protein; its primary function is to form a helical ribonucleoprotein complex with viral RNA (vRNA) ([@bib0095]). N plays an important and necessary role as an enhancer of coronavirus replicon activity ([@bib0005], [@bib0010]). Here, we constructed a single short hairpin RNA (shRNA) plasmid expression system that targeted the N gene and investigated whether shRNA-mediated RNA interference could inhibit PHEV replication in PK-15 cells.

The HEV-67N strain (GenBank accession no.: [AY078417](ncbi-n:AY078417)) was replicated in PK-15 cells ([@bib0065]). Prior to being infected with PHEV, the cells were maintained in MEM supplemented with 10% fetal bovine serum (FBS) and antibiotics (100 μg/ml streptomycin and 100 U/ml penicillin) in a 37 °C, 5% CO~2~ incubator overnight. When 70% of the virus-infected cells showed cytopathic effects (CPE), the cultures were collected, purified by sucrose density gradient centrifugation, and stored at −80 °C until use.

Based on recent research ([@bib0015]) and the experience of researchers from the Ambion Corporation ([@bib0040]) using GenBank sequences (GenBank accession no.: [AY078417](ncbi-n:AY078417), [NC_007732](ncbi-n:NC_007732)) for HEV-67N and VW527, the conserved areas were selected, and Ambion\'s online siRNA target design tool was utilized to choose the two best target sequences for targeting N. BLASTN searches were conducted on all sequences to ensure gene specificity. The targeted oligonucleotides were inserted into the pGPU6/GFP/Neo plasmid vectors using the *BbsI* and *BamHI* restriction sites to produce shN1 and shN2 (sequences shown [Table 1](#tbl0005){ref-type="table"} ); the negative control shRNA (shNC), which targeted GTTCTCCGAACGTGTCACGT sequences and did not match any gene, was purchased from Shanghai Genepharma Co, Ltd (Shanghai, China).Table 1List of shRNA sequences in this study.Target nameSequences of shRNA[a](#tblfn0005){ref-type="table-fn"}shN1 (nt7004--7024)Sense: 5′-cacc[GGTACTGGTACAGACACAACA]{.ul}***ttcaagaga***TGTTGTGTCTGTACCAGTACCTTTTTTg-3′\
Antisense: 5′-gatccAAAAAAGGTACTGGTACAGACACAACA***tctcttgaa***TGTTGTGTCTGTACCAGTACC-3′shN2 (nt7218--7238)Sense: 5′-cacc[GGCTATTCCGACTAGGTTTCC]{.ul}***ttcaagaga***GGAAACCTAGTCGGAATAGCCTTTTTTg-3′\
Antisense: 5′-gatccAAAAAAGGCTATTCCGACTAGGTTTCC***tctcttgaa***GGAAACCTAGTCGGAATAGCC-3′[^2]

PK-15 cells were seeded in 24-well plates and incubated for 24 h at 37 °C in a 5% CO~2~ atmosphere. When the cells were 70--80% confluent, they were washed and overlaid with transfection complexes containing 1.5 μg of shN1, 1.5 μg of shN2, or 1.5 μg of shNC, in 100 μL of MEM medium mixed with Lipofectamine™ 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s instructions. The transfection complexes were completely removed after incubating for 6 h, and the cells were infected with 400 TCID~50~ (10^4.49^) of PHEV. Non-transfected cells were used as a control.

To study the inhibitory effects of RNA interference on PHEV replication, the level of viral antigen produced in the PK-15 cells after shRNA transfection and viral infection was examined 48 h post-infection by an indirect immunofluorescence assay (IFA) using anti-PHEV serum. Infected cells were visualized by IFA, as has been described previously ([@bib0105]). Positive anti-PHEV serum and negative control serum were prepared, as described previously ([@bib0110]). Cells were washed three times with PBS and incubated with Cy3-conjugated rabbit anti-pig IgG (Sigma, St. Louis, MO, USA; 1:60) for 1 h. After washing, the cells were photographed and examined with an Olympus FV 1000 laser scanning confocal microscope. At 48 h post-PHEV infection, the majority of the non-transfected cells and the cells transfected with shNC exhibited red fluorescence in the cytoplasm, indicating that these cells were virus-producing ([Fig. 1](#fig0005){ref-type="fig"}A and C). By contrast, only a few cells in wells treated with shN1 and shN2 transfection displayed red fluorescence ([Fig. 1](#fig0005){ref-type="fig"}D and E), indicating that most of these cells were effectively protected by shRNAs and resisted viral infection.Fig. 1Protective effect of shRNA against PHEV infection. The viral infection in PK-15 cells was examined by IFA. (A) shNC transfection (stained with PHEV-positive serum); (B) shNC transfection (stained with PHEV-negative serum); (C) non-transfection (stained with PHEV-positive serum); (D) shN1 transfection; (E) shN2 transfection.

Oligonucleotides for the quantitation of PHEV by TaqMan real-time RT-PCR were designed using the corresponding GenBank sequences (GenBank accession no.: [AY078417](ncbi-n:AY078417), [NC_007732](ncbi-n:NC_007732)) for HEV-67N and VW527; the conserved areas were selected, and primers were designed for PHEV using Primer express 2.0. Three primers were synthesized (JiKang, Shanghai, China) for quantification of the PHEV genome by real-time PCR: 5′-AGCGATGAGGCTATTCCGACTA-3′ (NFP primer), 5′-TTGCCAGAATTGGCTCTACTACG-3′ (NRP primer), and 5′-FTTC-CGCCAGGCACGGTACTCCCP-3′ (TaqMan probe). The target region for real time RT-PCR spanned nucleotides 7210--7348 of the N protein gene of PHEV (GenBank accession no.: [AY078417](ncbi-n:AY078417)). Total RNA (100 ng) was extracted and purified using the Trizol LS Reagent (Invitrogen, Carlsbad, CA, USA). PCR was used to amplify the N gene with the NFP and NRP primers under conditions of 94 °C for 3 min, followed by 40 cycles of 94 °C for 30 s, 60 °C for 30 s, and 72 °C for 60 s, with a final extension at 72 °C for 7 min. The PCR product was gel-purified using an Agarose Gel DNA Extraction Kit (Axygen, Union, CA, USA) and then cloned into the pGEM-18T vector (Promega, Madison, WI, USA). The resulting plasmid, pT-N, for which the correct sequence was confirmed by direct sequencing, was selected as a quantitative standard for the determination of the viral RNA copy number. Real-time PCR was performed with the ABI PRISM^®^ 7000 Sequence Detection System using a QuantiTect™ Probe PCR Kit (Qiagen, Hilden, Germany) under the conditions of 95 °C for 3 min, followed by 40 cycles of denaturation at 95 °C for 30 s, annealing, and extension at 60 °C for 30 s. The quantitative standard curve for the determination of the PHEV genome copy number was created by real-time PCR of standard plasmid pT-N preparations at serial dilutions of 10^3^, 10^4^, 10^5^, 10^6^ and 10^7^  copies/μL. The specificity of the real-time PCR was confirmed by sequencing the product.

To quantify the effect of shRNA on viral replication at 48 h post-viral infection, the viral genome copy number was determined by real-time PCR, using the serially diluted plasmid pT-N as a standard. The *R* ^2^ value of the standard curve was 0.99, and the average amplification efficiency *E* was 0.993. Sequencing showed that the amplified fragment contained the expected portion of the PHEV genome, thereby demonstrating the specificity and reliability of the analysis. As shown in [Fig. 2](#fig0010){ref-type="fig"} , the copy number of the viral genome per nanogram of total RNA calculated from the standard curve was 8.79 × 10^4^  copies/ng of viral genome in the total RNA from the shNC-treated cells, which was similar to that observed in the mock transfected cells (non-transfected cells), whereas there were 2.67 × 10^4^ and 1.60 × 10^4^  copies/ng of the viral genome in total RNA from cells treated with shN1 and shN2, respectively. These values correspond to reductions of 70% and 82%, respectively.Fig. 2Real-time quantitative RT-PCR results indicate a significant decrease of N gene mRNA expression level by shN1 and shN2 at 48 h after virus infection. The values are shown as means of triplicates and three independent experiments. \*Significant difference from shNC groups (*P* \< 0.05).

To substantiate further the inhibitory effect of shN1 and shN2, the viral 50% tissue culture infectious dose (TCID~50~) was used to titrate PHEV at 48 h post-infection. Briefly, the cultures were collected, subjected to 3 freeze--thaw cycles, serially diluted 10-fold from 10^−1^ to 10^−8^, and added to PK-15 cells in 96-well plates. TCID~50~ was calculated using the Reed and Muench method ([@bib0080]). The results ([Fig. 3](#fig0015){ref-type="fig"} ) showed that in control cells transfected with shNC, the PHEV TCID~50~ reached 10^4.30^ at 48 h post-infection, which was similar to that observed in non-transfected cells. In contrast, the titers at 48 h post-infection were 10^2.45^ and 10^2.03^ for cells transfected with shN1 and shN2, respectively, which corresponded to 71- and 186-fold reductions compared to shNC-transfected cells. Our results demonstrated that shN1 and, especially, shN2 both blocked viral replication with very high efficiency, but the effects were transient (data not shown).Fig. 3Transfection with shN1 and shN2 reduces the viral titer in the PK-15 cells after 48 h of virus infection. At 48 h after virus infection, cell culture supernatants were collected for viral titration. All the data were obtained by experiments performed in triplicates and repeated three times. \*Significant difference from shNC group (*P* \< 0.05).

To conform further the effect of using RNA interference (RNAi), stably transfected lines were created. For shN2 transfection, 10^5^  cells per well were plated in six-well plates and transfected with 4 μg of shRNA duplex using Lipofectamine 2000 according to the manufacturer\'s instructions. After 48 h of incubation, the medium was replaced with MEM containing 1300 mg/ml G418. After maintenance for 2 weeks in selection media, resistant cell clones, named shN2-1, shN2-2 and shNC-1, were selected, cultured, infected with 400 TCID~50~ (10^4.49^) of PHEV per well in 24-well plates, and incubated at 37 °C for the various time periods indicated. To study PHEV-induced CPE ([Fig. 4](#fig0020){ref-type="fig"} ) at 12 h post-infection, cells were examined by phase-contrast microscopy every 4 h. The infected shNC-1 cells and non-transfected cells exhibited obvious morphological changes starting from the brims of the wells at 56 h post-infection, such as loss of the monolayer as well as rounding and shrinking of the cells. Analysis of cell morphology indicated that the negative control (shNC-1) had no inhibitory effect on PHEV-induced CPE compared with the mock control (non-transfected cells). In contrast, the trial group (shN2-1 and shN2-2) effectively blocked CPE in the cell cultures up to 120 h (data not shown).Fig. 4Effect of siRNAs on PHEV-induced CPE in PK-15 cells. Virus-produced CPE was observed at 56 h after virus incubation. (A) shNC-1; (B) non-transfection; (C) shN2-1; (D) shN2-2.

In addition, infectious virus production was determined by a TCID~50~ assay. [Fig. 5](#fig0025){ref-type="fig"} shows that titers of PHEV reached 10^4.31^, 10^4.46^, and 10^4.48^  TCID~50~/mL at 48 h, 56 h and 72 h post-infection, respectively, in shNC-1, followed by a gradual decrease in titer from 72 to 120 h post-infection. In contrast, titers at 48 h post-infection were 10^2.55^ and 10^2.14^  TCID~50~/mL in shN2-1 and shN2-2, corresponding to 57- and 147-fold reductions, respectively. Titers at 72 h post-infection were 10^2.79^ and 10^2.65^  TCID~50~/mL in shN2-1 and shN2-2, respectively, corresponding to 49- and 66-fold reductions. At 120 h post-infection, the viral titers were still 11- and 25-fold lower in shN2-1 and shN2-2, respectively, compared to that of shNC-1. The data indicate that the shRNA stably expressing cells experienced markedly inhibited infectious virus production, but the level of inhibition decreased as time progressed.Fig. 5Viable viral production in two siRNA stably expressing PK-15 cell clones (shN2-1, shN2-2). TCID~50~ are the means of three repeat titrations at the time points indicated. \**P* \< 0.05 vs. shNC stably expressing PK-15 cells (shNC-1).

To confirm the specificity of the RNAi effect and the absence of interferon activity in stably transfected lines, shN2-1, shN2-2 and shNC-1 were also challenged with 200 TCID~50~ (10^3.38^) of Pseudorabies virus (PRV) JL strain in a plaque counting assay, as has been described previously ([@bib0020]). No significant difference in plaque number and plaque size between mock control (non-transfected cells) and stably transfected lines was observed from 0 to 48 h after PRV infection (shown in [Fig. 6](#fig0030){ref-type="fig"} ).Fig. 6The stably transfected lines (shN2-1, shN2-2, shNC-1) failed to alter significantly plaque number or size (not shown) from 0 to 48 h after 200 TCID~50~ of PRV incubation. At 12, 24, 36 and 48 h after virus infection, respectively, the medium was removed, cells were fixed and stained, and the number of plaques was counted. All data were collected in triplicate wells and in three independent experiments.

PHEV is the only known CoV that is neurotropic in pigs. Recently, infection rates of PHEV have increased in some countries ([@bib0030], [@bib0085]); thus, pigs without antibodies to PHEV, such as SPF pigs, were threatened by a high risk of infection by PHEV ([@bib0075]). The study of PHEV replication and of the control or inhibition of this infection is of great significance because, currently, no effective preventative measures or cures exist for this disease.

RNAi provides effective antiviral defenses in plants and other organisms; so several studies have focused on harnessing RNAi to inhibit viral infection ([@bib0055]). However, the effectiveness of siRNA that has been transfected transiently into cells is restricted because of low transfection efficiency and the short-term persistence of silencing effects. Recently, the vector-based approach of shRNA interference has been developed to achieve stable, long-term, and highly specific suppression of gene expression in mammalian cells ([@bib0060], [@bib0090]). To explore the possibility of interrupting PHEV replication with siRNAs or shRNAs, siRNA expression plasmids targeting the N gene in PHEV have been synthesized.

N plays an important role in viral packaging. In the process of viral packaging, N acts as a bridge between the M protein and the viral RNA. The interaction of N and mRNA may affect on viral RNA transcription and replication. In addition, N is highly conserved among coronaviruses, is expressed during viral infection and has a strong immunogenicity. These features make the N gene coding region a good RNAi target site. Our results have shown that the replication of PHEV in cell culture can be disrupted by shRNAs targeting the N gene of PHEV.

It is clear from this study that the DNA vector-based shRNA approach, that is, the use of RNAi expression plasmids directed against the PHEV N gene, could effectively block expression of the viral target gene and inhibit viral replication. In addition, siRNA therapy can be directed at the different levels of viral function, such as transcription or translation. Based on the present data and the advantages of siRNA technology, we believe that siRNA is a potential therapeutic agent against chronic PHEV infection.
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